Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Innovative Life Science Strategies: Staying Ahead in a Competitive Market

Dec 03, 2025

Embracing Technological Advancements

In the rapidly evolving field of life sciences, staying ahead requires embracing technological advancements. The integration of technologies such as artificial intelligence, machine learning, and big data analytics is transforming the landscape. These technologies offer *unprecedented opportunities* for research and development, enabling scientists to analyze vast datasets with greater accuracy and speed.

artificial intelligence life sciences

AI-driven tools can enhance drug discovery processes, predict patient outcomes, and personalize treatment plans. By leveraging these innovations, companies can not only speed up development but also reduce costs, ensuring they remain competitive in a crowded market.

Utilizing Big Data

Big data is revolutionizing how life science companies approach research. The ability to collect and analyze large volumes of data allows for deeper insights into biological processes and disease mechanisms. By utilizing big data analytics, companies can identify trends and patterns that would be impossible to detect manually.

Moreover, big data facilitates collaboration across different sectors of the life sciences industry, leading to more comprehensive and integrated approaches to problem-solving. This collaborative effort helps in developing more effective and efficient therapies.

big data analytics

Fostering Collaboration and Partnerships

Collaboration and partnerships are essential for innovation in the life sciences. By working together, companies and research institutions can combine their strengths and resources to tackle complex challenges. Partnerships with technology firms, academic institutions, and healthcare providers can lead to groundbreaking discoveries and applications.

  • Joint research initiatives
  • Public-private partnerships
  • Cross-industry collaborations

These collaborations not only foster innovation but also help in sharing risks and rewards, making it easier to bring new products to market.

collaboration research

Adopting Agile Methodologies

The adoption of agile methodologies is becoming increasingly important in life sciences. Agile frameworks allow teams to be more flexible and responsive to changes. This adaptability is crucial in a field where new discoveries and technologies can rapidly alter the landscape.

By implementing agile practices, life science companies can accelerate their research and development cycles, reduce time to market, and better meet the needs of patients and healthcare providers.

Focusing on Patient-Centric Approaches

In the competitive life sciences market, a *patient-centric approach* is key to success. Understanding and addressing the needs and preferences of patients can lead to more effective treatments and improved patient satisfaction. Companies are increasingly using patient feedback and real-world data to guide their research and development efforts.

patient care

This focus on the patient helps in developing therapies that are not only effective but also align with patient lifestyles and expectations. It strengthens the connection between healthcare providers and patients, fostering trust and better health outcomes.

Ensuring Regulatory Compliance

Regulatory compliance is a critical aspect of the life sciences industry. Navigating the complex landscape of regulations requires diligence and expertise. Companies must stay informed about changes in regulatory requirements to ensure their products meet all necessary standards.

By prioritizing compliance, life science companies can avoid costly delays and potential legal issues, ensuring a smoother path to market for their innovative products.